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In a multicenter collaboration, we carried out T cellereplete, peripheral blood stem cell (PBSC) trans-
plantations from related, HLA-haploidentical donors with reduced-intensity conditioning (RIC) and post-
transplantation cyclophosphamide (Cy) as graft-versus-host disease (GVHD) prophylaxis in 55 patients
with high-risk hematologic disorders. Patients received 2 doses of Cy 50 mg/kg i.v. on days 3 and 4 after
infusion of PBSC (mean, 6.4  106/kg CD34þ cells; mean, 2.0  108/kg CD3þ cells). The median times to
neutrophil (500/mL) and platelet (>20,000/mL) recovery were 17 and 21 days respectively. All but 2 of the
patients achieved full engraftment. The 1-year cumulative incidences of grade II and grade III acute GVHD
were 53% and 8%, respectively. There were no cases of grade IV GVHD. The 2-year cumulative incidence of
chronic GHVD was 18%. With a median follow-up of 509 days, overall survival and event-free survival at
2 years were 48% and 51%, respectively. The 2-year cumulative incidences of nonrelapse mortality and relapse
were 23% and 28%, respectively. Our results suggest that PBSC can be substituted safely and effectively for
bone marrow as the graft source for haploidentical transplantation after RIC.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hemopoietic stem cell transplantation from
HLA-matched donors is curative in a proportion of patients
with hematologic malignancies, as well as in those with
inherited diseases, such as hemoglobinopathies and bone
marrow failure syndromes. A suitable HLA-identical sibling
donor will be available for about 30% to 35% of patients. For
Table1
Patient and Disease Characteristics
Characteristics Value
Total sample, N 55
Seattle FHCRC 20
London Guy’s and St. Thomas’ 7
London Kings College Hospital 18
Westmead Hospital 10
Age
Recipient, median (range), yr 49 (14-69)
Donor, median (range), yr 40 (15-73)
Sex, n (%)
Male 35 (64)
Female 20 (36)
Recipient ethnicity, n (%)
Caucasian 37 (67)
Afro-Caribbean 9 (16)
Asian 9 (16)
Donor relationship, n (%)
Mother 8 (15)
Father 5 (9)
Brother 8 (15)
Sister 12 (22)
Son 14 (25)
Daughter 8 (15)
CMV serostatus, n (%)
Recipient /donor  14 (25)
Recipient þ/donor  8 (15)
Recipient /donor þ 7 (13)
Recipient þ/donor þ 26 (47)
ABO compatibility, n (%)
Compatible 27 (49)
Minor mismatch 12 (22)
Major mismatch 15 (27)
Bidirectional mismatch 1 (2)
Time diagnosis-Allogeneic HCT, median months
(range)
23 (2-215)
Prior chemotherapy/radiotherapy lines median
(range), n
3 (1-15)
Prior transplantation, n (%)
Autologous 12 (22)
Months from Auto, median (range) 23 (6-106)
Allogeneic 7 (13)
Months from Allo, median (range) 6 (2-39)
Disease, n (%)
B-NHL 7 (13)
T-NHL 5 (9)
AML 16 (29)
HL 9 (16)
ALL 2 (4)
MDS 5 (9)
SAA 4 (7)
CLL 4 (7)
CML 3 (5)
Myeloid 24 (44)
Lymphoid 27 (49)
Aplastic Anemia 4 (7)
Disease status at HCT, n (%)
CR1 20 (36)
CR > 1 11 (20)
PR 9 (16)
SD 9 (16)
RD 2 (4)
PD 4 (7)
ASBMT/CIBMTR disease risk classiﬁcation, n (%) 51 (excludes AA)
Low risk 12 (24)
Intermediate risk 25 (49)
High risk 14 (25)
Cell dose/kg, mean (SD)
CD34þcells ( 106) 6.4 (1.6)
CD3þ cells ( 108) (n ¼ 19) 2.0 (1.4)
HLA mismatches, no (%)* HvG GvH
0 0 0
1 0 0
2 2 (4) 3 (7)
3 5 (12) 8 (18)
(Continued on next page)
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identifying a volunteer unrelated donor that is suitably
matched at HLA-A, -B, -C, and -DRB1 is population speciﬁc
ranging, from about 79% for Caucasian patients of European
descent to 30% to 50% for patients of other ethnic back-
grounds [1]. Even if a matched, unrelated donor is identiﬁed,
the likelihood of proceeding to transplantation is less than
50%, largely because of progression of disease during the
search process, which renders the patient ineligible for
transplantation [2]. For this substantial number of patients,
alternative donors, such as haploidentical family donors,
unrelated umbilical cord blood donors, or mismatched un-
related donors can bridge this gap, enabling transplantation.
Over the past decade, single-center and multicenter, coop-
erative group trials have shown that the administration of
high doses of cyclophosphamide 60 to 72 hours after the
infusion of bone marrow (BM) cells from related, hap-
loidentical donors (haplo-BM) enables engraftment with low
rates of rejection, acute and chronic graft-versus-host dis-
ease (GVHD), and nonrelapse mortality (NRM) [3-5]. In these
studies, disease relapse remained the major cause of treat-
ment failure. Currently, peripheral blood stem cells (PBSC)
are the preferred source of allografts because of ease of
collection, higher yields of CD34þ progenitor cells, faster
engraftment, and, in the case of matched sibling donor
transplantations, improved short and long term survival [6-
8]. However, PBSC products contain approximately 5 to 10
times higher numbers of CD3þ T cells than BM harvests [9],
which correlates with higher rates of acute and chronic
GHVD compared with BM [7,10-13]. In this report, we
describe outcomes after transplantation of patients with
high-risk hematologic disorders after reduced-intensity
conditioning (RIC), in which haplo-PBSC was substituted
for haplo-BM. Prophylaxis of GVHD included post-
transplantation cyclophosphamide (Cy) to eliminate allor-
eactive T cell populations, a calcineurin-inhibitor, and
mycophenolate mofetil (MMF). Although the rate of grade II
acute GVHD was higher, engraftment kinetics, grade III acute
GVHD, chronic GVHD, and survival outcomes were similar to
those reported for patients receiving haplo-BM.
PATIENTS AND METHODS
Eligibility Criteria
Consecutive, eligible patients from 4 centers, Guy’s and St Thomas’
Hospital, London; King’s College Hospital, London; Westmead Hospital,
Sydney; and the Fred Hutchinson Cancer Research Center, Seattle, who
underwent a stem cell transplantation with PBSC from related, HLA-
haploidentical donors between March 2009 and February 2013 were
included (Table 1). All patients had at least 160 days of follow-up. Results
were analyzed as of August 2013. All patients signed consent forms
approved by their local institutional review boards. Sharing of deidentiﬁed
transplantation data was approved by the institutional review boards of
each of the participating centers.
Patients were  70 years of age with a high-risk hematologic disorder
but lacked a suitably matched related or unrelated donor, deﬁned as a donor
with an 9 to 10/10 locus HLA match at HLA-A, HLA-B, HLA-C, HLA-DRB1, and
HLA-DQB1. An unrelated donor search was not required for a patient to be
eligible for this protocol, or a search could be abandoned if the clinical sit-
uation dictated an urgent transplantation. Clinical urgency was deﬁned as
6 to 8 weeks from referral to transplantation or a low likelihood of ﬁnding a
matched, unrelated donor. In this study, the only times that an unrelated
donor search were not performed were in the cases of 4 patients who had
rejected allografts from 10/10 matched donors and there was urgency in
performing a salvage transplantation.
Patients with acute leukemia were required to be in morphologic
complete remission. Patients with primary or secondary graft failure in a
prior allogeneic transplantation were also eligible. Patients were required to
have adequate organ function, deﬁned as left ventricular ejection fraction
 35%, forced expiratory volume in the ﬁrst second, functional vital capacity
or carbon monoxide corrected diffusion lung capacity > 50% of predicted;
Table1
(continued)
HLA mismatches, no (%)* HvG GvH
4 13 (29) 10 (22)
5 25 (56) 24 (53)
Median (range) 5 (2-5) 5 (2-5)
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome;
NHL, non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leukemia; HL,
Hodgkin lymphoma; ATLL, acute T leukemia lymphoma; T NHL, T non-
Hodgkin’s lymphoma; SAA, severe aplastic anemia; CML, chronic myeloid
leukemia; CR1, ﬁrst complete remission; CR > 1, subsequent complete
remission; PR, partial remission; SD, stable disease; RD, refractory/
progressive disease; FHCRC, Fred Hutchinson Cancer Research Center; CMV,
cytomegalovirus; B-NHL, B cell non-Hodgkin lymphoma; ALL, acute
lymphoblastic leukemia; ASBMT/CIBMTR, American Society for Blood and
Marrow Transplantation/Center for International Blood and Marrow
Transplant Research.
* n ¼ 45.
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alkaline phosphatase < 5 times the upper limit of normal, and serum
creatinine within the normal range for age or creatinine clearance or
calculated glomerular ﬁltration rate > 40 mL/min/1.73 m2. A Karnofsky
performance score of  60 was required. Patients who had undergone a
prior autologous transplantation were eligible, provided 3 months had
elapsed since the procedure.
Characteristics at Hematopoietic Cell Transplantation
Details regarding patient and donor characteristics are outlined in
Table 1. Of the 5 patients with myelodysplastic syndrome, prior chemo-
therapy was not administered in 2 patients with an International Prog-
nostic Scoring System score of low risk, 1 of whom had rejected 2 prior
allografts from the same HLA-matched, unrelated donor, and the other
patient had rejected a double allograft from 2 unrelated umbilical cord
blood donors. Two of 3 International Prognostic Scoring System high-risk
patients were treated with 4 cycles of 5-azacytidine (75 mg/m2 for 7 days
every 28 days). One of these 2 patients had cytogenetic progression and
was treated subsequently with induction chemotherapy (daunorubicin
50 mg/m2 for 3 days and cytarabine 100 mg/m2 twice daily for 10 days)
(DA 3 þ 10) before proceeding to haplo PBSC. The third high-risk patient
had previously received 10 cycles of lenalidomide and on disease pro-
gression to refractory anemia with excess blasts stage 2 was treated with
2 cycles of induction chemotherapy (ﬁrst with DA 3 þ 10and then DA
3 þ 8[8 days of cytarabine at the same dose as above]).
All 4 patients with severe aplastic anemia (SAA) had failed prior
immunosuppressive therapy and 2 of the 4 patients had subsequently
rejected stem cell transplantations from HLA-matched, unrelated donors.
None of the patients received further chemotherapy within 90 days of
haplo-PBSC transplantation. One patient with SAA/paroxysmal nocturnal
hemoglobinuria was treated with eculizumab before and during the trans-
plantation. MMF was stopped at day þ35; however, tacrolimus was main-
tained at levels of 10 to 15 ng/mL for 9 to 12 months after transplantation
and then tapered over a 3-month period.
HLA Matching and Donor Selection
Haplo-PBSC donors were required to be ﬁrst-degree relatives of the
patient, deﬁned as biologic parents, siblings, children, or half-siblings. Donor
and recipients were typed at HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-
DQB1 at the allelic level for the 45 patients enrolled at the London and
Seattle transplantation centers. At the Westmead center, 3 of 10 donor-
recipient pairs were typed at HLA-A, HLA-B, and HLA-DRB1 and 7 of 10
donor-recipient pairs were typed at HLA-A, HLA-B, HLA-C, and HLA-DRB1, as
per the preference of the local Red Cross laboratory. Donor-recipient pairs
were consideredHLA haploidentical if theywere genotypically identical for 1
allele at each of the typed loci. Donors were required to be  16 years of age
and were screened as per the American Association of Blood banks and
Foundation for Accreditation of Cellular Therapy/Joint Accreditation Com-
mittee ISCT EBMT guidelines. Donors were excluded if the recipient’s serum
contained antidonor HLA antibodies. If more than 1 possible donor were
identiﬁed, donor selection hierarchy was as follows: (1) donor-recipient
matching for cytomegalovirus (CMV) serology, and (2) donor-recipient red
blood cell compatibility. A previous report showed that increasing donor-
recipient HLA-mismatch did not have a detrimental effect after
nonmyeloablative HLA-haploidentical BM transplantation with post-
transplantation Cy [14]. Therefore, higher degrees of HLA matching were
not prioritized in donor selection.Conditioning Regimen and Immunosuppressive Therapies
Recipients were conditioned with ﬂudarabine 30 mg/m2/day i.v. daily
from days -6 to -2 (total dose of 150 mg/m2), Cy 14.5 mg/kg i.v. on days -6
and -5, and 2 Gy total body irradiation in a single dose on day -1 as pre-
viously described [4,5]. The dose of ﬂudarabine was adjusted for creatinine
clearance as clinically indicated. For patients with an actual body weight of
> 125% ideal body weight (IBW), Cy was dosed based on adjusted IBW.
Adjusted IBW was computed as the sum of the IBW and 25% of the dif-
ference between the actual and IBW. Sodium 2-sulfanylethanesulfonate
(MESNA) and i.v. hydration were administered for uro-protection. GVHD
prophylaxis consisted of Cy 50 mg/kg by i.v. infusion over 1 to 2 hours on
days þ3 (between 60 to 72 hours after PBSC infusion) and þ4 after
transplantation. Patients received tacrolimus and MMF beginning day þ5
after infusion of haplo-PBSC. MMF was given at a dose of 15 mg/kg every
8 hours with the maximum daily dose not exceeding 3 grams. MMF pro-
phylaxis was discontinued on day þ35 or continued at the discretion of the
treating center, if active GVHD was present. Tacrolimus was administered
to achieve a target trough level of 5 to 10 ng/mL with the goal of dis-
continuing at day þ180 after transplantation. Filgrastim was initiated at
day þ5 at a dose of 5 mg/kg/day and continued until the neutrophil count
was  1000/mL for 3 consecutive days.
Collection of Hemopoietic Stem Cells and Supportive Care
Filgrastim at a dose of 10 mg/kg (London and Sydney) or 16 mg/kg
(Seattle) actual body weight was administered subcutaneously once daily or
equally divided twice daily from day -5 to day -1, followed by collection of
PBSC by apheresis on day -1. The target dose of PBSC for infusion was 5 to
6  106 CD34þ cells/kg. If the target dose was met after the ﬁrst apheresis
procedure, PBSCwere stored overnight at 4C before infusion on day 0. If the
target dose was not met, a second apheresis was performed the next day.
PBSC in excess of the target dose were cryopreserved.
Antimicrobial prophylaxis was administered as per the institutional
protocols. All patients received prophylaxis for Pneumocystis jirovici
pneumonia, herpes simplex/zoster and Candida albicans. Prophylaxis for
mold was as per institutional protocols (secondary prophylaxis in Seattle
and Sydney and primary prophylaxis in London). Neutropenic patients
received prophylaxis with quinolones. Blood products were irradiated to
25 Gy before infusion. Transfusions for blood and platelets followed
institutional protocols. All patients, including CMV-negative patients,
received leuko-depleted blood products (“CMV-safe”). CMV DNA viral load
was monitored at least weekly by PCR of serum until day 100. Pre-emptive
therapy with either ganciclovir (5 mg/kg/i.v. twice daily) or foscarnet
(90 mg/kg twice daily) was initiated as per the institutional guidelines.
Patients in London were treated as in-patients from conditioning to
engraftment of neutrophils, whereas conditioning and transplantation in
Seattle and Sydney were outpatient procedures. Patients in Seattle and
Sydney were admitted as indicated for regimen-related toxicity or
infection.
GVHD Grading and Treatment
Acute GVHD was graded according to the consensus criteria [15].
Chronic GVHD was assessed as per the National Institutes of Health criteria
[16]. Each institution treated GVHD according to their local protocols.
Typically, progressive or grade III or IV acute GVHDwas treated initially with
1 to 2 mg/kg of methylprednisolone parenterally with optimization of the
dose of tacrolimus or the addition of MMF to tacrolimus.
Analyses of Donor Chimerism
Peripheral blood donor chimerism was tested at least on day þ28 after
transplantation and then as per institutional protocols. Chimerism was
studied by PCR analysis of short or variable nucleotide tandem repeats
unique to the donor and recipient. Chimerism was performed on at least
peripheral blood, CD3þ cells, and CD33þ or CD15þ cells. Patients were
considered fully donor chimeric if their unfractionated, CD3þ and CD33þ/
CD15þ fractions were  95% donor.
Statistical Methods
The outcomes are reported as of August 2013. The main outcomes of
interest were engraftment of neutrophils and platelets, incidence and
severity of both acute and chronic GVHD, NRM, overall survival (OS), and
event-free survival (EFS). Neutrophil engraftment was deﬁned as the time
from infusion of donor stem cells and the ﬁrst of 3 consecutive days with an
absolute neutrophil count of  500/mL. Platelet engraftment was similarly
deﬁned as the interval between donor stem cell infusion and the ﬁrst day of
a platelet count > 20,000/mL without a platelet transfusion in the preceding
7 days. Donor engraftment was deﬁned as a donor chimerism  95%. Graft
failure was deﬁned as  5% donor cells after transplantation not due to
progressive disease. NRM was deﬁned as death in the absence of detectable
Figure 1. Cumulative Incidence of (A) Grade II and Grade III acute graft-
versus-host disease and (B) NIH chronic graft-versus-host disease.
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using the KaplanMeier method [17] on an intent-to-treat basis. Probabilities
of acute GVHD, chronic GVHD, relapse, and NRM were summarized using
cumulative incidence estimates [18]. Death without engraftment was
considered a competing risk for engraftment; death without relapse was a
competing risk for relapse; relapse was a competing risk for NRM; graft
failure, relapse or death, without GVHD, were considered competing risks
for GVHD.
RESULTS
Patient and Graft Characteristics
By American Society for Blood and Marrow Trans-
plantation/Center for International Blood and Marrow
Transplant Research disease risk criteria, 24% of patients
were characterized as low risk, 49% as intermediate risk, and
25% as high risk (Table 1). Nineteen patients had received
prior stem cell transplantations: 12 (22%) had relapsed after
a previous autograft, whereas 2 (4%) had relapsed after
previous allografts (matched sibling  1, n ¼ 1; double um-
bilical cord blood  1, n ¼ 1), and 5 (9%) had failed to engraft
after prior allografts (matched sibling  2, n ¼ 1; matched
unrelated donor  1, n ¼ 1; matched unrelated donor  2,
n ¼ 2; double umbilical cord blood  1, n ¼ 1). Patients with
hematologic malignancies were divided approximately
equally between myeloid (44%) and lymphoid (49%) disor-
ders. Two-thirds of patients were Caucasian, whereas 32%
were from an ethnic minority population (Afro-Caribbean,
n ¼ 9; Asian, n ¼ 9).
Donor characteristics are also listed in Table 1. Donors
were children of recipients in 22 (40%) cases, siblings in 20
(37%) cases, and parents in 13 (24%) cases. In the 45 cases
where HLA typing was performed at 5 loci, there were a
median of 5 mismatches (range, 2 to 5) in the host-versus-
graft direction and a median of 5 mismatches (range, 2 to
5) in the graft-versus-host direction.
Engraftment
The median time to neutrophil recovery was 17 days
(range, 12 to 29 days). The median time to platelet recovery
was 21 days (range, 11 to 48 days); 6 patients did not reach a
platelet nadir< 20,000/mL. Primary graft failure occurred in 2
patients (4%): a patient with MDS/acute myeloid leukemia
who underwent a subsequent salvage transplantation from
an HLA-mismatched, unrelated donor but ultimately died of
relapsed disease and a patient with chronic myeloid leuke-
mia in second chronic phase who had autologous neutrophil
recovery at day þ23 and who is alive on tyrosine kinase
inhibitor therapy at day þ622. Full donor chimerism was
detected in unfractionated peripheral blood or CD3þ and
CD33þ or CD15þ fractions of peripheral blood in the
remaining 53 patients (96%) by day 28 and was sustained.
Infections
No invasive mold infections or Epstein Barr virus reac-
tivations were observed in any patients on study. CMV
reactivation occurred in 27 of 34 patients (79%) who were at
high risk for reactivation (donor seropositive/seronegative,
recipient seropositive) at a median of 33 days after trans-
plantation. Patients received pre-emptive therapy and no
case of CMV disease occurred. There were no cases of pri-
mary CMV infection.
Acute and Chronic GVHD
The cumulative incidences of grades II and grade III
acute GVHD at 1 year were 53% (95% conﬁdence interval
[CI], 40% to 66%) and 8% (95% CI, .4% to 15%), respectively(Figure 1A). No grade IV acute GVHD was observed. The
median time to onset of acute GVHD was 33 days. Two
patients developed late acute GVHD of the skin and gut at
113 and 261 days, respectively. Twenty-nine patients
developed grade II acute GVHD, most frequently involving
skin and lower gut in 15 patients. Seven of the 29 patients
developed mild stage I GVHD of the upper gastrointestinal
tract conﬁrmed by endoscopic biopsy [19] that resolved
completely after a short course of prednisone and beclo-
methasone [20]. Six of these patients were diagnosed in
the Seattle cohort. Four patients developed grade III acute
GVHD; skin and gut were involved in 1 patient; skin, gut
and liver in 2 patients; and gut and liver in 1 patient.
Twenty-three of 33 patients developing acute GVHD were
treated with systemic steroids. All patients responded to
initial therapy; 5 patients responded to .5 mg/kg of ste-
roids, 9 patients responded to 1 mg/kg of steroids, and 9
patients responded to 2 mg/kg of steroids, including the 4
patients with grade III GVHD.
The cumulative incidence of chronic GHVD was 16% (95%
CI, 6% to 26%) at 1 year and 18% (95% CI, 7% to 29%) at 2 years
(Figure 1B). Nine cases of chronic GVHD were observed. Four
cases were mild in severity, involving eye, gut, or liver. Three
cases were moderate, with 1 involving the skin, 1 involving
the lungs, and 1 involving serosal surfaces. Two cases were
severe, with 1 involving the lungs and 1 involving the eye,
skin, and liver. One patient experienced immune myopathy
and neuropathy at day þ40, consistent with the diagnosis of
Figure 2. (A) Cumulative incidence of relapse and nonrelapse mortality. (B)
Overall and event-free survival at 2 years after transplantation.
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steroids and i.v. immunoglobulin.
NRM and Relapse
The incidence of NRMwas 17% (95% CI, 7% to 27%) at 1 year
and 23% (95% CI, 10% to 35%) at 2 years after transplantation
(Figure 2A). There were 12 deaths from nonrelapse causes.
One patient died from complications associated with GVHD
and 1 patient died from diffuse alveolar hemorrhage. There
were 10 deaths from infections, including 4 viral infections
(parainﬂuenza, n ¼ 2; adenovirus, n ¼ 2), 4 bacterial in-
fections (P. aerugenosa, n ¼ 2; combined E. coli and
K. pneumonia, n¼ 1; and R. planticola, n¼ 1),1 yeast infection
(S. cerevisae), and 1 likely infection of unclear etiology. As
shown in Figure 2A, the cumulative incidence of relapse
(excluding the 4 patients with SAA) at 2 years after trans-
plantation was 28% (95% CI, 14% to 42%). Relapse occurred in
12 patients (acute T leukemia lymphoma, n ¼ 3; acute
myeloid leukemia, n ¼ 3; HIV-associated non-Hodgkin lym-
phoma, n¼ 1; anaplastic large cell lymphoma, n¼ 1; chronic
lymphoblastic leukemia, n ¼ 1; Hodgkin lymphoma, n ¼ 2;
chronic myeloid leukemia-second chronic phase, n ¼ 1).
OS and EFS
The median follow-up of surviving patients was 509
(range, 160 to 1203) days. OS and EFS at 1 year after trans-
plantation were 78% (95% CI, 64% to 87%) and 66% (95% CI,51% to 77%), respectively (Figure 2B). At 2 years after trans-
plantation, OS and EFS were similar at 48% (95% CI, 30% to
64%) and 51% (95% CI, 35% to 65%), respectively. The OS and
EFS curves appear to cross at 2 years due to small sample
variability (n ¼ 11). There were no signiﬁcant differences in
EFS or OS between patients with myeloid malignancies
compared with patients with lymphoid malignancies (data
not shown).
DISCUSSION
We have shown that substituting PBSC for BM as the
graft source in the Hopkins protocol for haploidentical
transplantation after RIC is feasible and does not adversely
affect outcomes. Our results suggest that BM or PBSC could
be used interchangeably as allograft sources for hap-
loidentical transplantation using this regimen.
The ﬁxed dose of CD34þ cells in the PBSC allograft (5 to
6 106/kg) was chosen for 2 reasons. Firstly, it approximated
the median CD34þ cell dose in BM allografts reported pre-
viously for this particular haploidentical protocol [4]. Sec-
ondly, it standardized the T cell dose, since an increased
number of T cells in PBSC products compared with BM
products has been associated with increased rates of acute
and chronic GVHD in the setting of HLA-matched related
[7,10,11] or unrelated donors [12,13]. In this study, the mean
number of CD3þ T cells in PBSC allografts (2.0  108 CD3þ
cells/kg) was about 5-fold higher than that reported previ-
ously for BM allografts [4]. The most striking effect of
increased Tcell dosewas an almost 2-fold increase in the rate
of grade II GVHD (53% with haplo-PBSC compared with 28%
to 32% with haplo-BM [4,5]), which responded completely to
steroid therapy in all treated cases.
The incidences of grade III acute GVHD and chronic GVHD
were low and similar to those reported previously for haplo-
BM [3,4]. Similar low rates of acute and chronic GVHD were
also observed in 2 small studies of haplo-PBSC transplantation
after myeloablative conditioning. The ﬁrst involved a 2-step
approach to haploidentical transplantation, in which pa-
tients were conditioned with high-dose total body irradiation
followed by donor lymphocyte infusion of 2 108 CD3þ cells/
kg (the same dose as in this study) and then high-dose Cy
before infusion of CD34þ-selected cells from a ﬁlgrastim-
mobilized PBSC donor [21]. In the second study, patients
were conditionedwith busulfan, ﬂudarabine, and Cy followed
by a PBSC allograft targeted at 5106 CD34 cells/kg and post-
transplantation Cy, tacrolimus, andMMF as in this study [22].
When compared with the haplo-BM protocol of RIC, rates
of nonengraftment (4% forhaplo-PBSC, 2% to 16% forhaplo-BM
[4,5,14]) and of neutrophil and platelet recovery (median 17
and 21 days, respectively, for haplo-PBSC; 16 and 24 days,
respectively, for haplo-BM [4,5]) were similar. Sustained
engraftmentwas achieved in the 5 patientswhere haplo-PBSC
was used as salvage for graft failure after prior allogeneic
transplantation from matched sibling, matched unrelated, or
double umbilical cord blood donors. Sustained engraftment
also was achieved in 5 patients with myelodysplastic syn-
drome and in 4 patients with SAA, which has not been re-
ported previously for haplo-BM using this regimen.
With a median follow-up for surviving patients of
17 months, the 2-year cumulative incidence of NRMwas 23%
for haplo-PBSC compared with 16% for haplo-BM [4]; the
2-year cumulative incidence of relapse was 28% for haplo-
PBSC compared with 58% for haplo-BM [4]; the 2-year
probability of EFS was 51% for haplo-PBSC compared with
26% for haplo-BM [4] and the 2-year probability of OS was
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[4]. For a comparable number of patients who underwent
transplantation in 4 separate centers using haplo-PBSC
compared with the multicenter study conducted by the
Blood and Marrow Transplant Clinical Trials Network using
haplo-BM [5], it appeared that transplantation outcomes of
patients with high-risk hematologic disorders after trans-
plantation with haplo-PBSC were comparable to those after
transplantation with haplo-BM.
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